文献速递肝病消化道肿瘤与早癌消化内镜

肝细胞癌监测新策略:简化MRI、生物标志物与获益分层

Emerging strategies for hepatocellular carcinoma surveillance: Abbreviated MRI, biomarkers and benefit stratification.
PubMed 文献 · J Hepatol · 2026-09-02

该专家意见评估了简化磁共振成像(aMRI)和血液生物标志物组合两类新兴肝细胞癌监测方法,并提出未来实施应基于预期监测获益而非仅HCC风险进行患者选择。aMRI中DCE-aMRI可无需回召成像确诊HCC,NC-aMRI在近期试验中灵敏度和特异度优于超声;生物标志物组合可提高依从性但需前瞻性验证。

要点

  • 现有半年一次超声联合AFP监测对早期HCC灵敏度欠佳且依从性差。
  • DCE-aMRI可无需回召成像确诊HCC,NC-aMRI灵敏度与特异度优于超声。
  • 监测选择应从风险分层转向获益分层,高危患者未必获益最大。

核心结论

  • 简化MRI和血液生物标志物组合是新兴HCC监测策略,若经验证其临床实施应基于预期监测获益而非仅HCC风险进行分层。

研究设计与样本

  • 专家意见,评估aMRI协议和血液生物标志物组合两类新兴HCC监测测试。

主要发现

  • DCE-aMRI可无需回召成像建立确定性HCC诊断,可能匹配全肝脏协议MRI的准确性。
  • NC-aMRI避免静脉造影剂,在近期试验中与超声相比表现出更优的灵敏度和特异度。
  • 血液生物标志物组合包括蛋白基础检测(GALAD、HES 2.0)和循环肿瘤DNA基础检测(Oncoguard、HelioLiver),可能提高依从性但面临方法学挑战。

关键数值与推荐

  • 临床实践指南推荐对肝硬化患者和选定慢性乙肝患者进行半年一次超声联合甲胎蛋白监测。
  • 血液生物标志物组合需严谨的前瞻性纵向评估以确定是否不仅实现更早可干预检测还带来更好临床结局。

临床怎么用

  • 未来实施aMRI和生物标志物组合时应基于预期监测获益而非仅HCC风险选择患者。
  • 需务实框架和预测工具估计个体化监测获益,因为最高HCC风险患者未必从早期检测中获益最大。

局限性

  • 缺乏随机试验证据证明肝硬化患者中减少HCC相关或全因死亡率。
  • 血液生物标志物组合面临方法学挑战,需前瞻性纵向评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma (HCC) surveillance with semi-annual ultrasound and alpha-fetoprotein is recommended in clinical practice guidelines for patients with cirrhosis and selected patients with chronic hepatitis B. However, this strategy has suboptimal sensitivity for early-stage HCC and poor real-world adherence; moreover, randomised trial evidence demonstrating reduced HCC-related or all-cause mortality in patients with cirrhosis is lacking. In this expert opinion, we evaluate two emerging categories of HCC surveillance tests - abbreviated magnetic resonance imaging (aMRI) protocols and blood-based biomarker panels - and propose that, if validated, their future clinical implementation should be guided not only by HCC risk, but by expected surveillance benefit. Protocols for aMRI seek to preserve the high diagnostic accuracy of full liver-protocol MRI while reducing scan time, cost, and patient burden. Dynamic contrast-enhanced aMRI (DCE-aMRI) can establish a definitive HCC diagnosis without recall imaging and may match the accuracy of full liver-protocol MRI. Non-contrast aMRI (NC-aMRI) avoids intravenous contrast and has demonstrated superior sensitivity and specificity compared with ultrasound in recent trials. Blood-based biomarker panels, including protein-based tests (GALAD, HES 2.0) and circulating tumour DNA-based assays (Oncoguard, HelioLiver) may improve adherence, but face methodological challenges and require rigorous, prospective longitudinal evaluation to determine whether they result not only in earlier actionable detection but also better clinical outcomes. We argue that selecting which patients should receive enhanced surveillance requires moving beyond risk stratification towards benefit stratification, i.e. basing surveillance recommendations not only on the patient's risk of developing HCC, but also on the probability that earlier-stage detection and receipt of effective treatment enabled by surveillance will improve clinical outcomes. Patients at the highest HCC risk do not necessarily stand to gain the most from earlier detection, underscoring the need for pragmatic frameworks and prediction tools that estimate individualised surveillance benefit.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Ioannou GN, Jepsen P, Rowe IA, et al. Emerging strategies for hepatocellular carcinoma surveillance: Abbreviated MRI, biomarkers and benefit stratification. J Hepatol. 2026. PMID: 42685984. doi:10.1016/j.jhep.2026.08.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。